CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: EIF2B5 (ImmuneEditome ID:8893)

1. Gene summary of enriched editing regions for EIF2B5

check button Gene summary
Gene informationGene symbol

EIF2B5

Gene ID

8893

GeneSynonymsCACH|CLE|EIF-2B|EIF2Bepsilon|LVWM|VWM5
GeneCytomap

3q27.1

GeneTypeprotein-coding
GeneDescriptiontranslation initiation factor eIF-2B subunit epsilon|eIF-2B GDP-GTP exchange factor subunit epsilon|eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa
GeneModificationdate20230517
UniprotIDQ13144;A0A3B3IS56;A0A3B3IT53;A0A3B3ISS1;C9JRD9;A0A3B3IUF2;A0A3B3ITQ2;A0A3B3ISA5;A0A3B3ISX3;A0A3B3IRP4;A0A3B3ISM8;A0A3B3IUB1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:184194661-184195193:+ENST00000444495.1ENSG00000145191.10EIF2B5intronicFLAM_A,AluSxchr3:184194661-184195193:+.alignment
chr3:184196958-184199201:+ENST00000444495.1ENSG00000145191.10EIF2B5intronicAluSx,AluJr,AluJb,AluY,AluSx1,MIR,(TG)n,LTR16A,AluSc8chr3:184196958-184199201:+.alignment
chr3:184263483-184264590:+ENST00000444495.1ENSG00000145191.10EIF2B5intronicMIRb,(AG)n,AluJr,AluSc,AluSz6,AluSx3,(TA)nchr3:184263483-184264590:+.alignment
chr3:184318470-184319003:+ENST00000444495.1ENSG00000145191.10EIF2B5intronicAluSzchr3:184318470-184319003:+.alignment


Top

2. Tumor-specific enriched editing regions for EIF2B5


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000145191.10,EIF2B5LUSCEAG8.2402e-03image
chr3:184196958-184199201:+UCECEER3.7665e-04image
ENSG00000145191.10,EIF2B5UCECEAG1.1948e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr3:184196958-184199201:+ESCACliEER3.2742e-024.6773e-02-0.3246image
ENSG00000145191.10,EIF2B5KIRCPathEAG2.5232e-021.1897e-02-0.1561image
ENSG00000145191.10,EIF2B5READPathEAG6.7225e-052.8576e-030.4093image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr3:184196958-184199201:+LUSCEER3.7218e-025.5337e-031.9792e+01image
ENSG00000145191.10,EIF2B5LUSCEAG3.7190e-031.6340e-021.0315e+01image

Top

3. Enriched editing regions and immune related genes for EIF2B5


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for EIF2B5


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:184196958-184199201:+
GBMEERIRENSG00000213689.5chr348465045:48466309:48466777:48467433-0.39721.4401e-031.9032e-07-0.4190imageNNNAT_cells_follicular_helperGSVA_HALLMARK_FATTY_ACID_METABOLISM

More results



Top

5. Enriched editing regions and immune infiltration for EIF2B5


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000145191.10,EIF2B5ACCEAGNeutrophils4.3245e-050.4950image
chr3:184196958-184199201:+BLCAEERMacrophages_M12.3350e-030.2179image
ENSG00000145191.10,EIF2B5BLCAEAGMacrophages_M17.3784e-030.1762image
chr3:184196958-184199201:+BRCAEERT_cells_CD4_memory_activated5.5431e-030.1131image
ENSG00000145191.10,EIF2B5BRCAEAGMast_cells_resting2.6140e-020.0858image
chr3:184196958-184199201:+CESCEERT_cells_follicular_helper2.2672e-02-0.1675image
ENSG00000145191.10,EIF2B5CESCEAGMast_cells_activated6.3526e-040.2317image
chr3:184196958-184199201:+COADEERB_cells_memory4.9244e-02-0.2916image
ENSG00000145191.10,EIF2B5COADEAGMast_cells_resting9.3153e-030.2503image
ENSG00000145191.10,EIF2B5DLBCEAGT_cells_gamma_delta4.5884e-020.4511image
chr3:184196958-184199201:+ESCAEERT_cells_CD4_naive4.9627e-020.1912image
ENSG00000145191.10,EIF2B5ESCAEAGMast_cells_activated3.8454e-020.1825image
chr3:184196958-184199201:+GBMEEREosinophils3.3036e-030.2424image
ENSG00000145191.10,EIF2B5GBMEAGEosinophils7.5279e-030.2196image
chr3:184196958-184199201:+HNSCEERNeutrophils4.4462e-060.3079image
ENSG00000145191.10,EIF2B5HNSCEAGNeutrophils1.1974e-040.2499image
ENSG00000145191.10,EIF2B5KIRCEAGT_cells_regulatory_(Tregs)1.1299e-02-0.1927image
ENSG00000145191.10,EIF2B5KIRPEAGT_cells_regulatory_(Tregs)2.6068e-02-0.1944image
chr3:184196958-184199201:+LGGEERDendritic_cells_activated8.7914e-040.1517image
ENSG00000145191.10,EIF2B5LGGEAGDendritic_cells_activated5.8507e-040.1554image
chr3:184196958-184199201:+LIHCEERT_cells_gamma_delta2.4511e-02-0.2687image
ENSG00000145191.10,EIF2B5LIHCEAGT_cells_gamma_delta2.2879e-02-0.2526image
chr3:184196958-184199201:+LUADEERT_cells_CD81.0698e-020.2342image
ENSG00000145191.10,EIF2B5LUADEAGMast_cells_activated3.7176e-020.1509image
chr3:184196958-184199201:+LUSCEERT_cells_CD4_memory_activated6.8532e-030.1558image
ENSG00000145191.10,EIF2B5LUSCEAGNeutrophils2.8707e-020.1134image
ENSG00000145191.10,EIF2B5MESOEAGT_cells_CD4_memory_activated3.5575e-03-0.4302image
chr3:184194661-184195193:+OVEERT_cells_CD4_naive1.5991e-030.3654image
chr3:184196958-184199201:+OVEERNeutrophils4.1465e-030.1872image
ENSG00000145191.10,EIF2B5OVEAGNeutrophils1.5658e-020.1552image
ENSG00000145191.10,EIF2B5PAADEAGT_cells_regulatory_(Tregs)2.0086e-02-0.2382image
chr3:184194661-184195193:+PCPGEERMacrophages_M15.1703e-030.3482image
chr3:184196958-184199201:+PCPGEERMacrophages_M04.6935e-060.3311image
ENSG00000145191.10,EIF2B5PCPGEAGMacrophages_M04.2163e-060.3326image
ENSG00000145191.10,EIF2B5PRADEAGT_cells_CD4_memory_resting1.0187e-080.2811image
chr3:184196958-184199201:+SKCMEERNK_cells_resting2.4217e-02-0.1708image
ENSG00000145191.10,EIF2B5SKCMEAGMonocytes3.9333e-02-0.1473image
chr3:184194661-184195193:+STADEERPlasma_cells4.2707e-030.3581image
ENSG00000145191.10,EIF2B5STADEAGT_cells_regulatory_(Tregs)6.2640e-03-0.1876image
ENSG00000145191.10,EIF2B5THCAEAGB_cells_memory9.9658e-03-0.1315image
ENSG00000145191.10,EIF2B5THYMEAGMacrophages_M12.1245e-030.3346image
chr3:184196958-184199201:+UCECEERMast_cells_activated2.3475e-02-0.2150image
ENSG00000145191.10,EIF2B5UCECEAGT_cells_regulatory_(Tregs)4.3354e-020.1848image
ENSG00000145191.10,EIF2B5UVMEAGEosinophils4.7394e-030.4430image


Top

6. Enriched editing regions and immune gene sets for EIF2B5


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr3:184196958-184199201:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER9.4588e-050.2773image
ENSG00000145191.10,EIF2B5BLCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.1976e-050.2706image
chr3:184196958-184199201:+BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEER9.6805e-100.2463image
ENSG00000145191.10,EIF2B5BRCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.7852e-080.2151image
ENSG00000145191.10,EIF2B5CESCGSVA_HALLMARK_DNA_REPAIREAG3.4253e-05-0.2792image
chr3:184196958-184199201:+CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.3055e-040.2611image
ENSG00000145191.10,EIF2B5CHOLGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG7.7833e-040.6626image
chr3:184196958-184199201:+COADGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.2569e-020.3357image
ENSG00000145191.10,EIF2B5DLBCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG1.4896e-020.5358image
ENSG00000145191.10,EIF2B5ESCAGSVA_HALLMARK_DNA_REPAIREAG2.2590e-020.2007image
chr3:184196958-184199201:+ESCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.1483e-020.1984image
ENSG00000145191.10,EIF2B5GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG5.6244e-030.2273image
chr3:184196958-184199201:+GBMGSVA_HALLMARK_HEME_METABOLISMEER1.0270e-030.2699image
chr3:184196958-184199201:+HNSCGSVA_HALLMARK_KRAS_SIGNALING_UPEER1.5899e-060.3212image
ENSG00000145191.10,EIF2B5HNSCGSVA_HALLMARK_KRAS_SIGNALING_UPEAG1.4353e-030.2081image
ENSG00000145191.10,EIF2B5KICHGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.8549e-03-0.4708image
ENSG00000145191.10,EIF2B5KIRCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG5.9881e-040.2591image
ENSG00000145191.10,EIF2B5KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.1999e-040.3096image
ENSG00000145191.10,EIF2B5LGGGSVA_HALLMARK_UV_RESPONSE_DNEAG5.9048e-080.2429image
chr3:184196958-184199201:+LGGGSVA_HALLMARK_UV_RESPONSE_DNEER1.1075e-080.2576image
chr3:184196958-184199201:+LIHCGSVA_HALLMARK_SPERMATOGENESISEER4.5763e-02-0.2396image
ENSG00000145191.10,EIF2B5LUADGSVA_HALLMARK_ADIPOGENESISEAG9.2223e-030.1880image
ENSG00000145191.10,EIF2B5LUSCGSVA_HALLMARK_PROTEIN_SECRETIONEAG9.2444e-030.1348image
chr3:184196958-184199201:+LUSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.9564e-070.2908image
chr3:184194661-184195193:+LUSCGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER7.7062e-03-0.5522image
ENSG00000145191.10,EIF2B5MESOGSVA_HALLMARK_HEME_METABOLISMEAG1.0719e-020.3810image
chr3:184194661-184195193:+OVGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER5.4913e-03-0.3240image
chr3:184196958-184199201:+OVGSVA_HALLMARK_KRAS_SIGNALING_UPEER2.5843e-060.3024image
ENSG00000145191.10,EIF2B5OVGSVA_HALLMARK_PEROXISOMEEAG1.6510e-030.2013image
chr3:184196958-184199201:+PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER4.7223e-050.2960image
chr3:184194661-184195193:+PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.3089e-020.2689image
ENSG00000145191.10,EIF2B5PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.1387e-050.2918image
ENSG00000145191.10,EIF2B5PRADGSVA_HALLMARK_UV_RESPONSE_DNEAG4.9590e-080.2681image
chr3:184196958-184199201:+SARCGSVA_HALLMARK_ANDROGEN_RESPONSEEER7.4773e-030.2088image
ENSG00000145191.10,EIF2B5SARCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG6.3080e-030.2087image
chr3:184196958-184199201:+SKCMGSVA_HALLMARK_UV_RESPONSE_DNEER7.8759e-040.2522image
ENSG00000145191.10,EIF2B5SKCMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.6617e-030.2135image
ENSG00000145191.10,EIF2B5STADGSVA_HALLMARK_DNA_REPAIREAG2.0876e-030.2107image
chr3:184196958-184199201:+STADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.4519e-040.2959image
ENSG00000145191.10,EIF2B5TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.6508e-030.3166image
ENSG00000145191.10,EIF2B5THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.2294e-080.2809image
ENSG00000145191.10,EIF2B5THYMGSVA_HALLMARK_COMPLEMENTEAG4.8238e-060.4808image
ENSG00000145191.10,EIF2B5UCECGSVA_HALLMARK_ADIPOGENESISEAG1.2503e-020.2274image
chr3:184196958-184199201:+UCECGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.0122e-020.2204image
ENSG00000145191.10,EIF2B5UCSGSVA_HALLMARK_E2F_TARGETSEAG1.5478e-020.3757image


Top

7. Enriched editing regions and drugs for EIF2B5


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000145191.10,EIF2B5ACCAICAREAG1.3004e-03-0.3994image
ENSG00000145191.10,EIF2B5BLCAElesclomolEAG4.6756e-040.2289image
chr3:184196958-184199201:+BLCAAICAREER3.3105e-04-0.2557image
chr3:184196958-184199201:+BRCAAZD6482EER7.0068e-07-0.2012image
ENSG00000145191.10,EIF2B5BRCAAZD6482EAG2.6332e-05-0.1616image
ENSG00000145191.10,EIF2B5CESCDocetaxelEAG2.4368e-050.2842image
chr3:184196958-184199201:+CESCEmbelinEER1.7617e-03-0.2285image
ENSG00000145191.10,EIF2B5CHOLEHT.1864EAG7.0640e-040.6665image
chr3:184196958-184199201:+COADLapatinibEER4.4154e-02-0.2982image
ENSG00000145191.10,EIF2B5DLBCAG.014699EAG3.4611e-030.6212image
chr3:184194661-184195193:+ESCAGemcitabineEER3.1122e-03-0.4139image
chr3:184196958-184199201:+ESCAAZ628EER9.0935e-03-0.2522image
ENSG00000145191.10,EIF2B5ESCAGDC.0449EAG7.9864e-03-0.2326image
chr3:184196958-184199201:+GBMBosutinibEER1.4978e-030.2613image
ENSG00000145191.10,EIF2B5GBMBIRB.0796EAG1.3313e-020.2037image
chr3:184196958-184199201:+HNSCEmbelinEER2.2187e-05-0.2856image
ENSG00000145191.10,EIF2B5HNSCJNJ.26854165EAG3.7608e-030.1895image
ENSG00000145191.10,EIF2B5KICHBryostatin.1EAG1.5570e-040.5757image
ENSG00000145191.10,EIF2B5KIRCBMS.536924EAG3.3268e-050.3108image
ENSG00000145191.10,EIF2B5KIRPBMS.708163EAG1.5547e-05-0.3677image
ENSG00000145191.10,EIF2B5LGGAMG.706EAG4.4112e-060.2065image
chr3:184196958-184199201:+LGGAMG.706EER1.3974e-060.2186image
ENSG00000145191.10,EIF2B5LIHCKIN001.135EAG2.2540e-020.2532image
chr3:184196958-184199201:+LUADCytarabineEER1.8100e-02-0.2173image
ENSG00000145191.10,EIF2B5LUADCCT007093EAG1.6077e-020.1740image
chr3:184194661-184195193:+LUSCATRAEER1.4411e-03-0.6367image
chr3:184196958-184199201:+LUSCGDC0941EER1.1467e-05-0.2503image
ENSG00000145191.10,EIF2B5LUSCGW843682XEAG1.0289e-050.2265image
ENSG00000145191.10,EIF2B5MESODMOGEAG8.6531e-03-0.3912image
chr3:184194661-184195193:+OVCGP.60474EER1.0343e-020.3004image
chr3:184196958-184199201:+OVCI.1040EER1.9718e-02-0.1527image
ENSG00000145191.10,EIF2B5OVBMS.708163EAG1.0576e-02-0.1641image
ENSG00000145191.10,EIF2B5PAADKU.55933EAG4.2166e-020.2089image
chr3:184196958-184199201:+PCPGGW843682XEER3.3234e-040.2624image
chr3:184194661-184195193:+PCPGGefitinibEER1.4134e-02-0.3078image
ENSG00000145191.10,EIF2B5PCPGGW843682XEAG2.0846e-040.2709image
ENSG00000145191.10,EIF2B5PRADCEP.701EAG8.0820e-110.3171image
ENSG00000145191.10,EIF2B5READMetforminEAG1.7976e-020.3635image
chr3:184196958-184199201:+SARCAICAREER1.1620e-04-0.2973image
ENSG00000145191.10,EIF2B5SARCAICAREAG2.8633e-05-0.3150image
chr3:184196958-184199201:+SKCMEmbelinEER2.9907e-02-0.1647image
ENSG00000145191.10,EIF2B5SKCMEmbelinEAG3.5086e-02-0.1506image
chr3:184196958-184199201:+STADATRAEER4.3724e-03-0.2242image
ENSG00000145191.10,EIF2B5STADBI.2536EAG2.0282e-060.3203image
ENSG00000145191.10,EIF2B5TGCTEHT.1864EAG1.3234e-02-0.2849image
ENSG00000145191.10,EIF2B5THCACytarabineEAG1.0719e-060.2462image
ENSG00000145191.10,EIF2B5THYMBMS.708163EAG3.0742e-05-0.4430image
ENSG00000145191.10,EIF2B5UCECAZ628EAG6.3764e-06-0.3990image
chr3:184196958-184199201:+UCECAZ628EER2.4916e-05-0.3887image
ENSG00000145191.10,EIF2B5UCSBosutinibEAG9.4812e-03-0.4004image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType